SG11201908322WA - Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors - Google Patents

Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors

Info

Publication number
SG11201908322WA
SG11201908322WA SG11201908322WA SG11201908322WA SG 11201908322W A SG11201908322W A SG 11201908322WA SG 11201908322W A SG11201908322W A SG 11201908322WA SG 11201908322W A SG11201908322W A SG 11201908322WA
Authority
SG
Singapore
Prior art keywords
connecticut
massachusetts
international
street
road
Prior art date
Application number
Inventor
Michael Aaron Brodney
Thomas Allen Chappie
Jinshan Michael Chen
Jotham Wadsworth Coe
Karen Jean Coffman
Paul Galatsis
Michelle Renee Garnsey
Christopher John Helal
Jaclyn Louise Henderson
Bethany Lyn Kormos
Ravi G Kurumbail
Luis Angel Martinez-Alsina
Martin Youngjin Pettersson
Matthew Richard Reese
Colin Richard Rose
Antonia Friederike Stepan
Patrick Robert Verhoest
Travis T Wager
Joseph Scott Warmus
Yuan Zhang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG11201908322WA publication Critical patent/SG11201908322WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

International Patent Classification: CO7D 471/04 (2006.01) A61P 25/16 (2006.01) CO7D 519/00 (2006.01) A61P 25/28 (2006.01) A61K 31/437 (2006.01) A61P 25/18 (2006.01) (21) International Application Number: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WIPO I PCT ~~ll~~~~~~~~ 011101010VIIIOH olo omio111111111flo ow (10) International Publication Number WO 2018/163066 Al PCT/IB2018/051439 (22) International Filing Date: 06 March 2018 (06.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/469,756 10 March 2017 (10.03.2017) US 62/629,152 12 February 2018 (12.02.2018) US (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, New York, New York 10017 (US). (72) Inventors: BRODNEY, Michael Aaron; 100 Upland Av- enue, Newton, Massachusetts 02461 (US). CHAPPIE, Thomas Allen; 59 Hemlock Hill Road, Carlisle, Massachu- setts 01741 (US). CHEN, Jinshan Michael; 39 Governors Way, Madison, Connecticut 06443 (US). COE, Jotham Wadsworth; 8 Bush Hill Drive, Niantic, Connecticut 06357 (US). COFFMAN, Karen Jean; 3 Clarence Ave., Paw- catuck, Connecticut 06379 (US). GALATSIS, Paul; 375 Cherry Street, Newton, Massachusetts 02465 (US). GAR- NSEY, Michelle Renee; 386 Morris Ave., Providence, Rhode Island 02906 (US). HELAL, Christopher John; 18 Elm Street, Mystic, Connecticut 06355 (US). HEN- DERSON, Jaclyn Louise; 36 Highland Avenue, Apt. 54, Cambridge, Massachusetts 02139 (US). KORMOS, Bethany Lyn; 46 Quincy Street, #3, Somerville, Massa- chusetts 02143 (US). KURUMBAIL, Ravi G.; 4 Harvest Glen, East Lyme, Connecticut 06333 (US). MARTINEZ- Declarations under Rule 4.17: ALSINA, Luis Angel; 58 Eagle Ridge Drive, Gales Ferry, Connecticut 06335 (US). PETTERSSON, Mar- tin Youngjin; 3 Gilson Road, Littleton, Massachusetts 01460 (US). REESE, Matthew Richard; 25 Ocean View Avenue, Mystic, Connecticut 06355 (US). ROSE, Colin Richard; 35 B Lower Bartlett Road, Quaker Hill, Connecti- cut 06375 (US). STEPAN, Antonia Friederike; Rotdorn- weg 8, 88400 Biberach An Der Riss (DE). VERHOEST, Patrick Robert; 23 Calvin Road, Newton, Massachusetts 02460 (US). WAGER, Travis T.; 465 Washington Street, Apt. 6, Brookline, Massachusetts 02446 (US). WARMUS, Joseph Scott; 18 Sable Drive, Ledyard, Connecticut 06339 (US). ZHANG, Yuan; 12103 Maple Tree Lane, East Lyme, Connecticut 06333 (US). (74) Agent: WALDRON, Roy F.; Pfizer Inc., 235 East 42nd Street, MS 235/9/S20, New York, New York 10017 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) W O 20 18/ 163066 Al (54) Title: NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS (57) : The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R 1 , R 2 and R 3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's dis- ease or Alzheimer's disease, cancer, Crohn's disease or leprosy. (I) [Continued on next page] WO 2018/163066 Al MIDEDIMOMMIDIIMEIEWHIDIENIEMIEMOVOIS Published: with international search report (Art. 21(3)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE
SG11201908322W 2017-03-10 2018-03-06 Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors SG11201908322WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469756P 2017-03-10 2017-03-10
US201862629152P 2018-02-12 2018-02-12
PCT/IB2018/051439 WO2018163066A1 (en) 2017-03-10 2018-03-06 Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors

Publications (1)

Publication Number Publication Date
SG11201908322WA true SG11201908322WA (en) 2019-10-30

Family

ID=61683855

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201908322W SG11201908322WA (en) 2017-03-10 2018-03-06 Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
SG10202110112T SG10202110112TA (en) 2017-03-10 2018-03-06 Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202110112T SG10202110112TA (en) 2017-03-10 2018-03-06 Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors

Country Status (13)

Country Link
US (1) US11312713B2 (en)
EP (1) EP3592741B1 (en)
JP (1) JP7219223B2 (en)
KR (1) KR102582626B1 (en)
CN (1) CN111051304B (en)
AU (1) AU2018230236B2 (en)
BR (1) BR112019018688A2 (en)
CA (1) CA3056030A1 (en)
IL (1) IL269214B (en)
MX (1) MX2019010756A (en)
SG (2) SG11201908322WA (en)
TW (1) TWI701246B (en)
WO (1) WO2018163066A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220561A (en) 2020-05-06 2023-02-17 Servier Lab New macrocyclic lrrk2 kinase inhibitors
AU2022239815A1 (en) 2021-03-18 2023-09-21 Les Laboratoires Servier Macrocyclic lrrk2 kinase inhibitors
WO2023220238A1 (en) * 2022-05-12 2023-11-16 Interline Therapeutics, Inc. Lrrk2 inhibitors
WO2023220247A1 (en) * 2022-05-12 2023-11-16 Interline Therapeutics, Inc. Lrrk2 inhibitors

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
DE3438830A1 (en) 1984-10-23 1986-04-30 Rentschler Arzneimittel PHARMACEUTICAL FORM CONTAINING NIFEDIPIN AND METHOD FOR THE PRODUCTION THEREOF
CA1335996C (en) 1988-02-16 1995-06-20 Susumu Takada 2-substituted carbonylimidazo¬4,5-c|quinolines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DK0580860T4 (en) 1991-04-16 2005-03-21 Nippon Shinyaku Co Ltd Process for preparing a solid dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (en) 1992-03-12 2002-03-11 大正製薬株式会社 Oral pharmaceutical composition
EP1308461A3 (en) 1993-01-25 2004-02-11 Takeda Chemical Industries, Ltd. Antibodies to beta-amyloids or their derivatives and use thereof
DE19504832A1 (en) 1995-02-14 1996-08-22 Basf Ag Solid drug preparations
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
SI0994728T1 (en) 1997-04-09 2009-02-28 Intellect Neurosciences Inc Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
PT901786E (en) 1997-08-11 2007-08-07 Pfizer Prod Inc Solid pharmaceutical dispersions with enhanced bioavailability
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
KR100767146B1 (en) 2000-02-24 2007-10-15 워싱톤 유니버시티 Humanized Antibodies That Sequester Amyloid Beta Peptide
AU2002239764B2 (en) 2000-11-03 2007-06-21 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
CA2451998A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238724A1 (en) 2002-08-23 2004-03-04 Bayer Ag New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance
DE10238723A1 (en) 2002-08-23 2004-03-11 Bayer Ag Phenyl substituted pyrazolyprimidines
JP2006519762A (en) 2002-10-09 2006-08-31 ライナット ニューロサイエンス コーポレイション Methods for treating Alzheimer's disease using antibodies against amyloid β peptide and compositions thereof
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
CA2528652A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
MY157827A (en) 2003-06-27 2016-07-29 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
EP1666061A1 (en) 2003-09-09 2006-06-07 Takeda Pharmaceutical Company Limited Use of antibody
AR046845A1 (en) 2003-11-21 2005-12-28 Novartis Ag DERIVATIVES OF 1H-IMIDAZO [4,5-C] QUINOLINE FOR THE TREATMENT OF PROTEIN-KINASE DEPENDENT DISEASES
JP2007519707A (en) 2004-02-02 2007-07-19 ファイザー・プロダクツ・インク Histamine-3 receptor modulator
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
WO2006036291A2 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
EP1827493A4 (en) 2004-12-22 2009-09-30 Univ St Louis Use of anti-abeta antibody to treat traumatic brain injury
PE20061323A1 (en) 2005-04-29 2007-02-09 Rinat Neuroscience Corp ANTIBODIES TARGETED AGAINST AMYLOID BETA PEPTIDE AND METHODS USING THEM
WO2006136924A1 (en) 2005-06-22 2006-12-28 Pfizer Products Inc. Histamine-3 receptor antagonists
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
CA2624625A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
CA2643055A1 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
JP4585610B2 (en) 2007-01-22 2010-11-24 ファイザー・プロダクツ・インク Tosylate salt of therapeutic compound and pharmaceutical composition thereof
ITMI20070890A1 (en) 2007-05-04 2008-11-05 Sifi Spa OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
JP5863058B2 (en) 2010-05-17 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 1H-imidazo [4,5-c] quinoline
AR082827A1 (en) 2010-09-02 2013-01-09 Glaxo Group Ltd ARIL-METILOXI-BENZAMIDA COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OR PROFILAXIS OF PARKINSON'S DISEASE
EP2632260A4 (en) 2010-10-29 2015-06-17 Merck Sharp & Dohme Leucine-rich repeat kinase enzyme activity
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
US20150218172A1 (en) 2012-10-04 2015-08-06 Pfizer Limited Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
US10000482B2 (en) * 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
ITTO20130694A1 (en) 2013-08-14 2015-02-15 Umbra Meccanotecnica WASHPIPE JOINT FOR A PETROLIFY DRILLING SYSTEM
UA115388C2 (en) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016108130A1 (en) 2014-12-30 2016-07-07 Sun Pharmaceutical Industries Limited Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds
WO2017046675A1 (en) * 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
KR20190003997A (en) 2016-06-01 2019-01-10 해롤드 리차드 헬스트롬 Treatment of dry eye syndrome using parasympathetic and anti-sympathetic agents
IL269215B (en) * 2017-03-10 2022-09-01 Pfizer Cyclic substituted imidazo[4,5-c]quinoline derivatives

Also Published As

Publication number Publication date
RU2019131727A (en) 2021-04-12
EP3592741A1 (en) 2020-01-15
EP3592741B1 (en) 2023-02-15
AU2018230236B2 (en) 2022-05-19
CN111051304B (en) 2022-12-27
WO2018163066A1 (en) 2018-09-13
AU2018230236A1 (en) 2019-10-31
JP2020510046A (en) 2020-04-02
US20210355117A1 (en) 2021-11-18
US11312713B2 (en) 2022-04-26
BR112019018688A2 (en) 2020-04-07
IL269214B (en) 2022-03-01
KR102582626B1 (en) 2023-09-22
CN111051304A (en) 2020-04-21
MX2019010756A (en) 2020-01-20
TWI701246B (en) 2020-08-11
IL269214A (en) 2019-11-28
SG10202110112TA (en) 2021-10-28
KR20190138793A (en) 2019-12-16
CA3056030A1 (en) 2018-09-13
RU2019131727A3 (en) 2021-04-26
JP7219223B2 (en) 2023-02-07
TW201900642A (en) 2019-01-01

Similar Documents

Publication Publication Date Title
SG11201408044QA (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
SG11201908322WA (en) Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201809922YA (en) Pyrazole derivatives as plasma kallikrein inhibitors
SG11201811414TA (en) Heterocyclic compounds as immunomodulators
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201805001UA (en) Method of treating influenza a
SG11201805202VA (en) 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS
SG11201811712QA (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11201808650QA (en) Methods of treating ocular conditions
SG11201908065YA (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
SG11201903842YA (en) Combination treatment with antibody-drug conjugates and parp inhibitors